NIH launches clinical trials of COVID-19 blood-clotting treatments
The National Institutes of Health yesterday announced the launch of two of three planned, worldwide phase 3 clinical trials of varying types of blood thinners to treat adults with COVID-19.
Trials will include hospitalized and non-hospitalized patients; the expected third trial will later focus on those discharged after hospitalization for moderate-to-severe disease.
NIH said research shows many COVID-19 patients who died suffered from blood clots throughout their bodies; these blood thinners, known as ACTIV-4 antithrombotics, could provide insights for care.
Related News Articles
Headline
The Occupational Safety and Health Administration today announced a 60-day extension of the comment period on its proposed rule to remove the remaining…
Headline
COVID-19 infections are growing or likely growing in 45 states and not changing in five states, according to the latest data from the Centers for Disease…
Headline
The Food and Drug Administration July 15 announced a recall by Sandoz on certain lots of cefazolin, due to the lots being mislabeled as penicillin G potassium…
Headline
The Food and Drug Administration July 10 approved Moderna’s Spikevax COVID-19 vaccine for children under 12 with at least one underlying condition that…
Headline
The Occupational Safety and Health Administration June 30 released a proposed rule to remove what remains of its emergency temporary standard for occupational…
Headline
Department of Health and Human Services Secretary Robert F. Kennedy Jr. May 27 announced in a post on X that the Centers for Disease Control and Prevention…